scholarly journals Editorial: Epigenetic Reprogramming and Cancer Development Volume II

2022 ◽  
Vol 9 ◽  
Author(s):  
Isidro Sánchez-García ◽  
Carolina Vicente-Dueñas ◽  
Geoffrey Brown
Keyword(s):  
Epigenetic Reprogramming ◽  
Cancer Development

scholarly journals SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Caroline McCarthy ◽  
Joseph Sacco ◽  
Stefano Fedele ◽  
Michael Ho ◽  
Stephen Porter ◽  
...  
Keyword(s):  
High Risk ◽  
Sodium Valproate ◽  
Study Protocol ◽  
Epigenetic Reprogramming ◽  
Epithelial Dysplasia ◽  
Phase Iii ◽  
Cancer Development ◽  
Randomised Control Trial ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial

Abstract Background Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, randomised control trial of VPA as a chemopreventive agent in patients with high-risk oral epithelial dysplasia (OED). The aim of the trial is to gather preliminary evidence of the clinical and biological effects of VPA upon OED and assess the feasibility and acceptability of such a trial, with a view to inform a future definitive phase III study. Methods One hundred and ten patients with high-risk OED will be recruited from up to 10 secondary care sites in the UK and randomised into either VPA or observation only for 4 months. Women of childbearing potential will be excluded due to the teratogenic properties of VPA. Tissue and blood samples will be collected prior to randomisation and on the last day of the intervention/observation-only period (end of 4 months). Clinical measurement and additional safety bloods will be taken at multiple time points during the trial. The primary outcome will be a composite, surrogate endpoint of change in lesion size, change in grade of dysplasia and change in LOH profile at 8 key microsatellite regions. Feasibility outcomes will include recruitment targets, compliance with the study protocol and adverse effects. A qualitative sub-study will explore patient experience and perception of the trial. Discussion The current management options for patients with high-risk OED are limited and mostly include surgical resection and clinical surveillance. However, there remains little evidence whether surgery can effectively lead to a notable reduction in the risk of oral cancer development. Similarly, surveillance is associated with concerns regarding delayed diagnosis of OED progressing to malignancy. The SAVER trial provides an opportunity to investigate the effects of a repurposed, inexpensive and well-tolerated medication as a potential chemopreventive strategy for patients with high-risk OED. The clinical and biological findings of SAVER will inform the appropriateness, design and feasibility of a definitive phase III trial. Trial registration The trial is registered with the European Clinical Trials Database (Eudra-CT 2018-000197-30). (http://www.isrctn.com/ISRCTN12448611). The trial was prospectively registered on 24/04/2018.

scholarly journals Editorial: Epigenetic Reprogramming and Cancer Development

2020 ◽  
Vol 8 ◽  
Author(s):  
Geoffrey Brown ◽  
Carolina Vicente-Dueñas ◽  
Isidro Sánchez-García
Keyword(s):  
Epigenetic Reprogramming ◽  
Cancer Development

Increased serum MMP-2, MMP-7, MMP-9, TIMP-1 and TIMP-2 levels in colorectal cancer development

2011 ◽  
Vol 49 (05) ◽  
Author(s):  
I Hritz ◽  
Z Varga ◽  
M Juhász ◽  
P Miheller ◽  
Z Tulassay ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Development

Metaplasia — A Transdifferentiatlon Process that Facilitates Cancer Development: The Model of Gastric Intestinal Metaplasia

2006 ◽  
Vol 12 (1-2) ◽  
pp. 3-26 ◽  
Author(s):  
Patricia Mesquita ◽  
Raquel Almeida ◽  
Nuno Lunet ◽  
Celso A. Reis ◽  
Luis Filipe Santos Silva ◽  
...  
Keyword(s):  
Intestinal Metaplasia ◽  
Cancer Development ◽  
Gastric Intestinal Metaplasia

NREP Bridges TGF-ß Signaling and Lipid Metabolism in the Epigenetic Reprogramming of NAFLD in the Offspring of Insulin-Resistant Parents

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 46-OR
Author(s):  
DARIO F. DE JESUS ◽  
KAZUKI ORIME ◽  
CHIH-HAO WANG ◽  
JIANG HU ◽  
ERCUMENT DIRICE ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Epigenetic Reprogramming ◽  
Insulin Resistant

A combination of omega-3 fatty acids and a butyrate-producing fiber mitigates colon cancer development

2006 ◽  
Author(s):  
Dr. Joanne R. Lupton ◽  
Dr. Nancy D. Turner ◽  
Dr. Leslie Braby ◽  
Dr. John Ford ◽  
Dr. Raymond J. Carroll ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Colon Cancer ◽  
Cancer Development ◽  
Omega 3 Fatty Acids ◽  
Omega 3

Identification of BAP1-associated MicroRNAs and Implications in Cancer Development

2019 ◽  
pp. 1-4
Author(s):  
Tikam Chand ◽  
Tikam Chand
Keyword(s):  
Gene Regulation ◽  
In Silico ◽  
Mirna Target ◽  
Target Prediction ◽  
Differential Regulation ◽  
Cancer Development ◽  
Mirna Target Prediction ◽  
Cancer Types ◽  
In Silico Tools

Having role in gene regulation and silencing, miRNAs have been implicated in development and progression of a number of diseases, including cancer. Herein, I present potential miRNAs associated with BAP1 gene identified using in-silico tools such as TargetScan and Exiqon miRNA Target Prediction. I identified fifteen highly conserved miRNA (hsa-miR-423-5p, hsa-miR-3184-5p, hsa-miR-4319, hsa-miR125b-5p, hsa-miR-125a-5p, hsa-miR-6893-3p, hsa-miR-200b-3p, hsa-miR-200c-3p, hsa-miR-505-3p.1, hsa-miR-429, hsa-miR-370-3p, hsa-miR-125a-5p, hsa-miR-141-3p, hsa-miR-200a-3p, and hsa-miR-429) associated with BAP1 gene. We also predicted the differential regulation of these twelve miRNAs in different cancer types.

Sign in / Sign up

Export Citation Format

Share Document